A new publication from the University of Kentucky focuses on the rationale, study design, and protocol for the randomized controlled trial INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression (INCREASE) – a trial designed to test the efficacy of a medication therapy management intervention to reduce inappropriate medication use, bolster cognitive reserve, and ultimately delay symptomatic Alzheimer’s disease.
Investigators note that the course of Alzheimer’s disease (AD) includes a 10 to 20-year preclinical period with progressive accumulation of amyloid plaques and neurofibrillary tangles in the absence of symptomatic cognitive or functional decline. The duration of this preclinical stage in part depends on the rate of pathologic progression, which is offset by compensatory mechanisms referred to as cognitive reserve (CR). Comorbid medical conditions, psychosocial stressors, and inappropriate medication use may lower CR, hastening the onset of symptomatic AD.
The multidisciplinary research team for the INCREASE trial includes faculty from the UK Colleges of pharmacy, public health, and medicine – linked by affiliation with the UK Sanders-Brown Center on Aging. Dr. Daniela Moga, associate professor of pharmacy practice and science at the UK College of Pharmacy and associate professor of Epidemiology at the University of Kentucky College of Public Health, is first author of the article published in Trials. Dr. Erin Abner, associate professor of epidemiology, is among the co-authors.Friday Letter Submission, Publish on January 10